Science
Product Ambitions
The development of the product, QR-01, is rooted in scientific evidence that highlights the disruption of QR-01 in treating patients with aggressive periodontitis. While QR-01 is engineered to address periodontitis, its holistic health benefits extend well beyond oral care. Oral infections, beyond causing localized damage, carry broader health implications, potentially contributing to the development of new systemic diseases.
Background
Periodontitis is a persistent inflammatory disease that affects the gums and the supporting structures of teeth. While antibiotics have traditionally been a standard treatment for periodontitis, the emergence of antibiotic resistance poses a significant challenge to their long-term efficacy. This concern has highlighted the pressing need for the development of new treatment modalities, which can be used either as standalone therapies or in conjunction with existing treatments. Our perspective is that the creation of a new drug that can work in synergy with dental procedures, rather than replacing them, is likely to be met with a positive response from dental professionals.
QR-01 holds huge potential to become a future treatment of periodontitis.
Antimicrobial peptides hold significant promise as novel therapeutic agents for both diagnosing and potentially treating periodontal disease. Their most immediate potential lies in serving as topical adjuvant agents when combined with conventional periodontal therapy, enhancing the overall efficacy of periodontal disease treatment. This makes them particularly appealing for oral diseases due to the convenience and suitability of topical applications. Importantly, their use does not contribute to the development of antibiotic resistance, a concern associated with antibiotics commonly used to treat more life-threatening bacterial infections. In this context, QR-01 plays a pivotal role in the prevention and treatment of severe forms of periodontitis. QR-01 exhibits diverse functions such as antimicrobial efficacy in regulating chemotactic activity, the release of inflammatory mediators, cell differentiation, and apoptosis. In conditions such as bone fractures, periodontitis, apical periodontitis, and osteomyelitis, the risk of bacterial infection is notably high. Therefore, effective bone regenerative agents should possess antimicrobial properties to prevent infection. QR-01, with its broad-spectrum antimicrobial activity, may represent a promising advancement in the fields of bone and periodontium regeneration, offering a new horizon for therapeutic possibilities.
Market / Statistics
The global market for periodontal disease therapeutics estimated to cross $1.3 billion in 2029, growing at a CAGR of 9.0% over the forecast period, driven by aging population, lack of public awareness, higher incidence and prevalence in North America, Europe, Asia and Latin America, and increased use of tobacco-related products.
Size Industry
Periodontal Market Size Industry Outlook (2022 to 2032) The global periodontal - periodontitis and gingivitis etc. - market size is expected to enjoy a valuation of US$ 9.1 billion in the year 2022, and further expand at a CAGR rate of 10.4% to reach a valuation of approx. US$ 24.4 billion by the year 2032.
Market share
Periodontal disease is one of the most common diseases in America, affecting nearly 65 million adults over age 30. According to a recent study by Future Market Insights, device type in the product segment is leading the market with a share of about 77.6% in the year 2021, within the global market.
Periodontitis is a major risk factor for several severe and life- threatening diseases.
QR-01 is a natural peptide that is produced by the human body as part of the immune system. QR-01 has both pro-inflammatory and anti-inflammatory effects, depending on the context and the environment. QR-01 can promote wound healing by stimulating angiogenesis, collagen synthesis, and epithelialization, as well as preventing infection and scarring. The QR-01 family of peptides are classified as antimicrobial peptides (AMPs). The AMP family also includes the defensins. Whilst the defensins share common structural features, QR-01 peptides are highly heterogeneous. QR-01 can promote inflammation and immune response to fight against infections and tumors, but it can also inhibit inflammation and prevent tissue damage and chronic diseases. Therefore, QR-01 is a dual-function peptide that can modulate the balance between pro- and anti-inflammatory response. QR-01 is an antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. These peptides are potent, broad spectrum antimicrobials, which demonstrate potential as novel therapeutic agents. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to functioning as immunomodulators. These peptides are potent, broad spectrum antimicrobial effect that can modulate the immune system which demonstrate potential as novel therapeutic agents.